

Published in final edited form as:

*Mucosal Immunol.* 2013 March ; 6(2): 309–323. doi:10.1038/mi.2012.73.

## Altered Generation of Induced Regulatory T cells In the FVB.*mdr1a*<sup>-/-</sup> Mouse Model of Colitis

Scott M. Tanner<sup>1</sup>, Elizabeth M. Staley, PhD<sup>1</sup>, and Robin G. Lorenz, MD, PhD<sup>1,2</sup>

<sup>1</sup>Department of Pathology at the University of Alabama at Birmingham

<sup>2</sup>Department of Microbiology at the University of Alabama at Birmingham

### Abstract

The FVB.*mdr1a*<sup>-/-</sup> mouse, lacking the small molecule pump P-glycoprotein (P-gp), is a commonly used model for the study of spontaneous T cell mediated colitis. In addition, *MDR1* polymorphisms and P-gp deficiency in humans have been linked to the development of ulcerative colitis. We now demonstrate that mice with P-gp deficiency have decreased levels of Foxp3<sup>+</sup> regulatory T cells (Treg) in the intestinal lamina propria. This decrease is not due to either increased Treg apoptosis, altered Treg trafficking, or enhanced Treg plasticity to become Foxp3<sup>+</sup>IL-17<sup>+</sup> cells. Instead, P-gp deficiency appears to restrict the development of induced Treg cells (iTreg), as fewer Foxp3<sup>+</sup> iTregs developed from naïve FVB.*mdr1a*<sup>-/-</sup> T cells both upon TGF-β treatment *in vitro* and after adoptive transfer into FVB.*rag2*<sup>-/-</sup> recipients. Rather, *in vitro* TGF-β treatment results in a IL-17<sup>+</sup>CD4<sup>+</sup> T cell. This failure of iTregs to develop explains the decrease in Foxp3<sup>+</sup> Tregs in the FVB.*mdr1a*<sup>-/-</sup> intestine, representing a need to investigate this novel disease mechanism in human inflammatory bowel disease patients with *MDR1* polymorphisms.

### INTRODUCTION

Crohn's Disease and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that demonstrate chronic inflammation throughout the digestive tract. A recognized animal model of IBD is the p-glycoprotein (P-gp) deficient FVB mouse. These mice lack the multidrug resistance (*mdr1a*) gene and have been described to spontaneously develop T cell mediated colitis.<sup>1, 2</sup> P-gp is an ATP-dependent, transmembrane small molecule efflux pump (ABCB1), first described to confer resistance to several chemotherapeutic drugs and recently linked to caspase-3 dependent apoptosis.<sup>3-5</sup> P-gp expression has been identified on both epithelial and immune cells, including CD8<sup>+</sup> cells and dendritic cells (DCs).<sup>6-10</sup> Although P-gp deficiency has been linked to decreased epithelial barrier function, our lab has recently shown that P-gp deficiency also alters the response of immune cells in FVB.*mdr1a*<sup>-/-</sup> mice.<sup>11</sup> Importantly, several polymorphisms of the human *mdr1a* homolog, MDR1, have been linked to UC, making this a relevant model with which to study the disease.<sup>12-14</sup>

Address correspondence to: Dr. Robin G. Lorenz, Department of Pathology, University of Alabama at Birmingham, 1825 University Blvd., SHEL 602, Birmingham, AL 35294-2182. Phone: 205-934-0676. Fax: 205-996-9113. rlorenz@uab.edu.

The authors declare no conflict of interest.

SUPPLEMENTARY MATERIAL is linked to the online version of the paper at <http://www.nature.com/mi>

### DISCLOSURE

The authors declare no conflict of interest.

The role of CD4<sup>+</sup> regulatory T cells (Treg) in the development of colitis has become a recent focal point of IBD research. Treg can be of naturally occurring (nTreg) or induced (iTreg) origin, and are believed to suppress immune activity through several mechanisms, including the secretion of immunosuppressive molecules such as interleukin (IL)-10.<sup>15–17</sup> Both nTregs and iTregs are most commonly identified by the expression of the transcription factor Foxp3.<sup>18, 19</sup> While nTregs arise naturally in the thymus, iTregs are generated in the periphery. TGF- $\beta$  has been shown as an important molecule in the induction of iTregs in both mice and humans, and these cells are generated in response to inflammation.<sup>15, 20–23</sup> Both subsets of Tregs, nTreg and iTreg, are believed to play an important role in gut homeostasis and limiting intestinal inflammation.<sup>24, 25</sup>

Regulatory T cells have also been studied extensively in human IBD. It has been found that while Foxp3<sup>+</sup> Tregs are decreased in peripheral blood, Tregs from the colonic mucosa of IBD patients appear to function normally to suppress T effector cell (Teff) proliferation *in vitro* using a conventional cell contact assay.<sup>26–28</sup> In addition, treatment of patients with recombinant IL-10, a classic immunosuppressive cytokine produced by Tregs, has not yielded positive results.<sup>29, 30</sup> These observations suggest there could be another deficiency in regulatory T cells unrelated to the number of cells, cell contact inhibition, or the secretion of IL-10 playing a role in human IBD.

In this study, we investigated the function of Tregs from FVB.*mdr1a*<sup>-/-</sup> prior to the development of histological intestinal inflammation.<sup>31</sup> There are normal levels of Foxp3<sup>+</sup> Tregs in the spleen and these Tregs are functional in cell contact suppression assays; however, there are fewer CD4<sup>+</sup>Foxp3<sup>+</sup> cells in the intestines of FVB.*mdr1a*<sup>-/-</sup> mice. Interestingly, there were only minor changes in Treg apoptosis and the known gut homing markers were not altered in a way that would explain the decrease in intestinal Tregs. FVB.*mdr1a*<sup>-/-</sup> mice also had no change in Foxp3<sup>+</sup>IL-17<sup>+</sup> or Foxp3<sup>+</sup>IFN- $\gamma$ <sup>+</sup> cells in the intestinal lamina propria. However, fewer Foxp3<sup>+</sup> iTreg cells developed from naive FVB.*mdr1a*<sup>-/-</sup> T cells both upon TGF- $\beta$  treatment *in vitro* and after adoptive transfer into FVB.*rag2*<sup>-/-</sup> recipients, suggesting that iTregs have altered induction in the absence of P-gp, resulting in an inability to suppress colonic inflammation.

## RESULTS

### **FVB.*mdr1a*<sup>-/-</sup> mice have fewer intestinal Tregs, and FVB.*mdr1a*<sup>-/-</sup> Tregs display reduced suppression *in vitro***

In order to investigate the role of Tregs in the development of colitis in the FVB.*mdr1a*<sup>-/-</sup> mouse, we first evaluated the number and percentages of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in the FVB control and FVB.*mdr1a*<sup>-/-</sup> mice. Cells were isolated from the spleen, thymus, mesenteric lymph nodes (MLN), Peyer's patches (PP), small intestinal lamina propria (LP), and colonic LP of 6–8-week-old mice (prior to the development of intestinal inflammation) and subsequently stained for CD4 and Foxp3. Total lymphocyte numbers were found to be similar between the two groups in all tissues, however an increase was observed in the percentage of CD4<sup>+</sup> cells in the spleen, PP, and colonic LP (Figures 1a and b). Increased levels of CD4<sup>+</sup> cells in FVB.*mdr1a*<sup>-/-</sup> mice could indicate early stages of inflammation. Treg percentages in the spleen, thymus, MLN and colonic LP were similar between FVB and FVB.*mdr1a*<sup>-/-</sup>. Interestingly, FVB.*mdr1a*<sup>-/-</sup> mice had significantly fewer CD4<sup>+</sup>Foxp3<sup>+</sup> cells in the PP and small intestinal LP (Figure 1b). CD4<sup>+</sup>Foxp3<sup>+</sup> cell numbers mirrored the percentage observations (Figure 1c). Although inflammation is seen primarily in the colon in this model, several recent studies have shown that regulatory cell induction in the small intestine is necessary to protect from colitis, leading us to further investigate this decrease in Tregs in the PP and small intestine.<sup>32, 33</sup>

Although P-gp has been shown on CD8<sup>+</sup> cells, its expression on CD4<sup>+</sup> Tregs is unknown. To test for the presence P-gp expression on Tregs, a real time PCR assay for the P-gp gene (*Abcb1a*) was performed. MACS isolated CD4<sup>+</sup>CD25<sup>+</sup> splenocytes expressed significantly higher levels of *Abcb1a* RNA compared to CD4<sup>+</sup>CD25<sup>-</sup> cells (Figure 1d). Isolated splenic CD4<sup>+</sup>CD25<sup>+</sup> cells showed approximately 80% Foxp3<sup>+</sup> expression, indicating a majority of the CD4<sup>+</sup>CD25<sup>+</sup> cells used for this analysis were indeed Foxp3<sup>+</sup> Treg cells (Supplementary Figure S1). To test the function of P-gp on splenic CD4<sup>+</sup>CD25<sup>+</sup> cells, the efflux of Rhodamine-123 (R-123), a fluorescent P-gp specific substrate was evaluated, utilizing CD8<sup>+</sup> cells as a positive control (Supplementary Figure S2b).<sup>7, 34</sup> As seen in Figure 1e, very little flux was observed from the splenic CD4<sup>+</sup>CD25<sup>-</sup> Teff cells, while one-third of the splenic CD4<sup>+</sup>CD25<sup>+</sup> Treg cells were capable of fluxing the dye out completely, indicating P-gp activity on this subset of cells. A timecourse of P-gp functional activity indicated that even after four hours for R123 efflux, only a minority of the CD4<sup>+</sup>CD25<sup>-</sup> cells were able to flux out the R123 dye (Supplementary Figure S2a). In addition, cells isolated from FVB.*mdr1a*<sup>-/-</sup> mice were unable to significantly efflux R-123 (Figure 1e).

Because P-gp appears to only be functional on a subset of Tregs, we then evaluated whether the absence of P-gp altered the function of FVB.*mdr1a*<sup>-/-</sup> Tregs. To accomplish this, an *in vitro* cell suppression assay was performed in which splenic FVB and FVB.*mdr1a*<sup>-/-</sup> Teff and Treg cells were isolated via MACS and cultured for 96 hours in the presence of plate bound anti-CD3 and soluble anti-CD28. FVB Teff cells were cultured with or without FVB or FVB.*mdr1a*<sup>-/-</sup> Tregs to compare suppression. Proliferation was measured by <sup>3</sup>H-thymidine incorporation. FVB.*mdr1a*<sup>-/-</sup> Tregs were somewhat less capable of suppressing Teff proliferation to the same extent as the FVB Treg at 1:1 and 2:1 (Teff:Treg) ratio (Figure 2a). However, FVB.*mdr1a*<sup>-/-</sup> Tregs are able to successfully suppress the proliferation of wild type FVB Teff, and FVB Treg could also suppress FVB.*mdr1a*<sup>-/-</sup> Teff cells (Supplementary Figure S3).

While the function of the Tregs in a cell contact dependent system was important to test, we also wanted to determine what cytokines might be present in this culture system. To test this, cell supernatants were removed from the cells after 72 hours of culture and analyzed by a multiplex system for IFN- $\gamma$ , IL-10, IL-17A, and TNF- $\alpha$  (Figure 2b). Interestingly, no suppression of IFN- $\gamma$  or IL-17A was observed in the presence of either FVB or FVB.*mdr1a*<sup>-/-</sup> Tregs. In addition, wild type FVB Tregs seemed to suppress the secretion of TNF- $\alpha$  to a greater extent than FVB.*mdr1a*<sup>-/-</sup> Tregs, while production of IL-10 was similar.

### **Increased apoptosis and altered trafficking of Foxp3<sup>+</sup> cells does not appear to be responsible for the decrease in Treg cells in FVB.*mdr1a*<sup>-/-</sup> intestines**

While our data indicated that the FVB.*mdr1a*<sup>-/-</sup> Tregs that are present can suppress Teff proliferation *in vitro*, this information did not explain the reduced number and percentages of Tregs that was observed in the FVB.*mdr1a*<sup>-/-</sup> PP and small intestinal LP. It has been shown in human tumors and leukemia cell lines that P-gp can be protective of caspase induced apoptosis.<sup>4, 5</sup> Therefore, it is possible that Tregs deficient in P-gp may be more susceptible to apoptosis, resulting in fewer Foxp3<sup>+</sup> cells. To examine this potential mechanism, sections of intestine were fixed in cold Bouin's fixative and stained with fluorescently labeled antibodies for Foxp3 and cleaved caspase-3. Upon observation under the microscope, there were no Foxp3<sup>+</sup> cells that were also cleaved caspase-3<sup>+</sup> in either the FVB or FVB.*mdr1a*<sup>-/-</sup> colonic samples (Figure 3b). As a positive apoptosis control, we also analyzed sections of PP. Multiple cells were positive for cleaved caspase-3, however none of these were found to also be expressing Foxp3 in either strain (Figure 3a). Because of this very low level of apoptosis seen *in vivo*, we also wanted to check the sensitivity of Foxp3<sup>+</sup> cells to the induction of apoptosis. To test this, cells were isolated, stimulated with anti-Fas ligand (CD95) overnight, and subsequently stained for CD4, Foxp3 and cleaved caspase-3.

Cells were then analyzed via flow cytometry (Figure 3c). Significant changes were observed in spleen, MLN, and PP, with anti-Fas ligand (CD95) inducing fewer cleaved caspase-3<sup>+</sup> apoptotic Foxp3<sup>+</sup> cells in the FVB.*mdr1a*<sup>-/-</sup> spleen and PP. This observation would seem to suggest that the FVB.*mdr1a*<sup>-/-</sup> mice do not have decreased Foxp3<sup>+</sup> cells due to altered sensitivity to apoptosis. However, there was a slight, but significant, increase in Foxp3<sup>+</sup>cleaved caspase-3<sup>+</sup> cells in the FVB.*mdr1a*<sup>-/-</sup> MLN. The importance of this observation is unclear, as it is unknown if MLNs are required for the presence of Tregs in the small intestinal or colonic LP. No difference in anti-CD95 induced apoptosis was observed between FVB and FVB.*mdr1a*<sup>-/-</sup> Foxp3<sup>+</sup> cells from the intestinal LP, supporting the conclusion that increased apoptosis in intestinal tissue is not the cause for the decreased Treg numbers.

Another possible mechanism to explain fewer Tregs in the FVB.*mdr1a*<sup>-/-</sup> intestine is altered trafficking of Tregs to the intestinal tissues of FVB.*mdr1a*<sup>-/-</sup> mice. To test this, we stained cells from spleen, MLN, PP, and intestinal LP for Foxp3 and the intestinal trafficking markers  $\alpha_4\beta_7$ , CD103 ( $\alpha_E$  integrin), CCR6, and CCR9 (Figure 4a and b). The trafficking marker with the most obvious changes in expression was CCR6, which demonstrated significantly increased expression on CD4<sup>+</sup>Foxp3<sup>+</sup> cells in FVB.*mdr1a*<sup>-/-</sup> MLN, PP, small intestinal LP and colonic LP. However, this data should be evaluated in light of the fact that CCR6 was also increased in CD4<sup>+</sup>Foxp3<sup>-</sup> cells from FVB.*mdr1a*<sup>-/-</sup> in these same tissues (Supplementary Figure S4). While no striking differences were observed in CCR9 and CD103 on CD4<sup>+</sup>Foxp3<sup>+</sup> cells in the colonic LP, FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>Foxp3<sup>+</sup> cells did display a small, but numerically significant increase in  $\alpha_4\beta_7$  and CD103 in small intestinal LP. Based on the magnitude of this change, it not clear that it would have a significant functional effect, especially when it is considered that the mean fluorescence intensity (MFI) of these trafficking markers was similar between the two strains (Supplementary Figure S5). In addition, FVB.*mdr1a*<sup>-/-</sup> Tregs showed a slight, but significant decrease in  $\alpha_4\beta_7$  in PP and increase of CD103 in splenic Tregs. Total cell numbers for each marker did not show many significant changes (Figure 4b). In addition, chemotaxis assays for CCL20 and CCL25, the chemokines for CCR6 and CCR9 respectively, did not show any difference in the functional ability of FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>+</sup> cells to traffic. SDF-1 $\alpha$  was utilized as a positive control to assure trafficking was occurring (Supplementary Figure S6). Taken together, these data do not explain the significant decrease in CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs is observed in the FVB.*mdr1a*<sup>-/-</sup> PP and small intestine LP, although there is still a possibility that other trafficking phenomena could be playing a role in this model.

### P-gp deficiency does not increase Treg plasticity

It has recently been shown in several disease models, including type 1 diabetes and IBD, that Treg cells can convert to other T helper phenotypes, especially to Th17-like cells.<sup>35-37</sup> This led us to another possible explanation for a reduction Tregs in FVB.*mdr1a*<sup>-/-</sup> intestines: Foxp3<sup>+</sup> cells are converting to secretion of proinflammatory cytokines, making them more like a Th1 or Th17 cell. To test for this, cells were isolated from spleen, MLN, PP, and intestinal LP (Figure 5). Cells were then stimulated with PMA and ionomycin in the presence of GolgiStop and subsequently stained for CD4, Foxp3, and IL-17, or IFN- $\gamma$ . There was no increase in CD4<sup>+</sup>Foxp3<sup>+</sup>IL-17<sup>+</sup> or CD4<sup>+</sup>Foxp3<sup>+</sup>IFN- $\gamma$ <sup>+</sup> cells between the FVB and FVB.*mdr1a*<sup>-/-</sup> mice in any tissue, including the colonic LP. This would indicate that Foxp3 cells from FVB.*mdr1a*<sup>-/-</sup> mouse strain is not any more likely to secrete proinflammatory cytokines than the FVB control. While the FVB.*mdr1a*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells did not appear to produce more IFN- $\gamma$  or IL-17, FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>Foxp3<sup>-</sup> Teff cells did produce higher levels of IL-17, particularly in the colon (Supplementary Figure S7). This is indicative of early inflammation being detected by immune assays in these mice, before it could be detected histologically. Our laboratory has also previously shown that

FVB.*mdr1a*<sup>-/-</sup> mice have increased INF- $\gamma$  and IL-17 mRNA levels in the intestine at a young age.<sup>31</sup>

### FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> naïve T cells fail to become iTreg cells upon treatment with TGF- $\beta$

Although P-gp deficient Foxp3<sup>+</sup> Treg cells do not have an increased propensity to shift to the production of inflammatory cytokines, it is possible that these mice may have a defect in the induction of iTregs from naïve T cells. iTregs can be induced *in vitro* by treatment with TGF- $\beta$ ; however, if IL-6 is also present then Th17 are the predominant T cell produced.<sup>15, 38</sup> As there is an increased percentage of CD4<sup>+</sup> cells that produce IL-17 in the colon of FVB.*mdr1a*<sup>-/-</sup> mice, we next investigated the hypothesis that P-gp deficiency altered the iTreg/Th17 axis (Figure 6). CD4<sup>+</sup>CD25<sup>-</sup> or CD4<sup>+</sup>CD25<sup>+</sup> cells were cultured in the presence IL-6 or TGF- $\beta$ , as well as in combination. The cells were then analyzed for Foxp3 and IL-17 expression via flow cytometry, and the supernatants were analyzed for IL-10, IL-17A and IFN- $\gamma$  via ELISA. Interestingly, treatment with TGF- $\beta$ , a cytokine known to induce Foxp3 expression and to be responsible for iTreg generation, resulted in significantly fewer Foxp3<sup>+</sup> cells from the FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> cultures (21.74 $\pm$ 0.12%) as the FVB CD4<sup>+</sup>CD25<sup>-</sup> cultures (38.91 $\pm$ 1.83%). In addition, TGF- $\beta$  treated FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells produced significantly more IL-17 secreting cells (6.75 $\pm$ 0.24% vs. 1.14 $\pm$ 0.08%) and Foxp3<sup>+</sup>IL-17<sup>+</sup> double positive cells (5.45 $\pm$ 0.45% vs. 0.80 $\pm$ 0.28%) than FVB CD4<sup>+</sup>CD25<sup>-</sup> cells. IL-6 had smaller effects, as IL-6 only treatment did produce more IL-17<sup>+</sup> cells from the FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> starting culture, although these cells did produce more IL-17<sup>+</sup> cells with no treatment (Figure 6a). When Treg-like CD4<sup>+</sup>CD25<sup>+</sup> cells were used as the starting population, there was no significant difference in Foxp3<sup>+</sup> cells between the FVB and FVB.*mdr1a*<sup>-/-</sup> untreated cultures, aside from a small decrease in FVB.*mdr1a*<sup>-/-</sup> Foxp3<sup>+</sup> cells when treated with both IL-6 and TGF- $\beta$  (Figure 6A). These data would suggest FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup> cells have a reduced ability to become iTregs in the presence of TGF- $\beta$ . To attempt to estimate the number of iTregs and nTregs *in vivo*, we also looked at the expression of Helios. Although controversial, Helios has been described as a transcription factor that is thought to be expressed in nTreg, but not iTreg cells.<sup>39, 40</sup> Percentages of Foxp3<sup>+</sup>Helios<sup>+</sup> cells were similar between FVB and FVB.*mdr1a*<sup>-/-</sup>, showing that nTreg percentages were unchanged between FVB and FVB.*mdr1a*<sup>-/-</sup> groups, however increased numbers of Foxp3<sup>+</sup>Helios<sup>+</sup> cells were observed in the FVB.*mdr1a*<sup>-/-</sup> MLN, PP and colonic LP (Supplementary Figure S8), suggesting increased proportions of nTregs vs iTregs.

In addition to the cell expression data above, the cytokines secreted by these cells also support the fact that FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> Teff seem to be more likely to produce proinflammatory cytokines than FVB cells. Although FVB.*mdr1a*<sup>-/-</sup> Teff cells secrete more IL-10 when treated with TGF- $\beta$ , FVB.*mdr1a*<sup>-/-</sup> Teff secrete much more IL-17A at baseline and under most treatments. In addition, FVB.*mdr1a*<sup>-/-</sup> Teff cells also secrete significantly more IFN- $\gamma$  under most conditions (Figure 6B). There were few differences in cytokine secretion when CD4<sup>+</sup>CD25<sup>+</sup> Treg cells were treated (Figure 6b). Lastly, it is important to note that freshly isolated splenic CD4<sup>+</sup>Foxp3<sup>-</sup> (and CD4<sup>+</sup>Foxp3<sup>+</sup>) cells from FVB and FVB.*mdr1a*<sup>-/-</sup> express similar levels of the activation markers CD44, CD62L, and CD69, indicating that the activation states of these cells is the same (data not shown). Taken together, these data suggest that naïve FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells responded to TGF- $\beta$  by increasing IL-10 and IL-17 production, instead of becoming true Foxp3-expressing iTreg cells. This mechanism is one explanation for the decrease in CD4<sup>+</sup>Foxp3<sup>+</sup> cells in the intestines of FVB.*mdr1a*<sup>-/-</sup> mice.



### FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells show impaired Foxp3<sup>+</sup> iTreg generation *in vivo*

Although the decreased level of Foxp3<sup>+</sup> iTreg generation *in vitro* was intriguing, it was also necessary to determine if this defect in iTreg generation occurred *in vivo*. An adoptive transfer was performed to test the ability of FVB.*mdr1a*<sup>-/-</sup> naïve CD4<sup>+</sup>CD25<sup>-</sup> cells to become Foxp3<sup>+</sup> iTreg cells *in vivo*. Splenic CD4<sup>+</sup>CD25<sup>-</sup> cells from FVB and FVB.*mdr1a*<sup>-/-</sup> were sorted via FACS. Sorted CD4<sup>+</sup>CD25<sup>-</sup> cells were found to be approximately 0.3% Foxp3<sup>+</sup>. 1×10<sup>6</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells from either FVB or FVB.*mdr1a*<sup>-/-</sup> were injected i.p. into FVB.*Rag2*<sup>-/-</sup> recipients. After 2 weeks, spleen, MLN, and intestinal lamina propria tissue was harvested and analyzed for Foxp3 expression, indicating the generation of iTreg cells. In concordance with the *in vitro* data, FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells appear to also have an impaired ability to generate iTreg cells *in vivo*. FVB.*mdr1a*<sup>-/-</sup> had a significantly smaller percentage of Foxp3<sup>+</sup> cells in the CD4<sup>+</sup> population in both the spleen (4.53% vs. 1.73%) and the MLN (4.16% vs. 1.39%), as well as decreased total Foxp3<sup>+</sup> numbers in both tissues (Figure 7). No Foxp3<sup>+</sup> cells were detected in the intestinal (small intestine or colon) lamina propria in the recipients of either strain.

## DISCUSSION

Several *MDR1* polymorphisms, which decrease P-gp efflux function, have been associated with human IBD.<sup>12-14</sup> In addition, FVB mice deficient in P-gp also develop a spontaneous, T cell mediated colitis.<sup>1, 2</sup> While some studies have shown FVB.*mdr1a*<sup>-/-</sup> mice to have altered intestinal barrier function due to P-gp expression in intestinal epithelial cells, a recent study by our laboratory suggests that a hematopoietic component in these animals also plays an important role in disease development.<sup>11, 41, 42</sup> Our current study supports the conclusion that in the absence of P-gp, the CD4<sup>+</sup>CD25<sup>+</sup> suppression of CD4<sup>+</sup> cell proliferation *in vitro* is sub-optimal, and the generation of Foxp3<sup>+</sup> cells from CD4<sup>+</sup>CD25<sup>-</sup> cells both *in vitro* and *in vivo* is dramatically inhibited. In order to determine if expression of P-gp on CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells could play a role in this defective generation of Foxp3<sup>+</sup> cells, we first determine if Tregs expressed P-gp. Indeed, increased levels of *Abcb1a* (P-gp) RNA was detected in CD4<sup>+</sup>CD25<sup>+</sup> Tregs and P-gp activity is detected in a higher percentage of CD4<sup>+</sup>CD25<sup>+</sup> cells, than in CD4<sup>+</sup>CD25<sup>-</sup> cells. More importantly, we also observed a decrease in CD4<sup>+</sup>Foxp3<sup>+</sup> Treg cells in the PP and small intestinal LP of FVB.*mdr1a*<sup>-/-</sup> mice approximately 4 weeks before histological intestinal inflammation typically occurs, implying that this could be a potential mechanism leading to the development of disease. However, we did not detect a decrease in CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in the colonic LP, although inflammation in the FVB.*mdr1a*<sup>-/-</sup> model of colitis is typically limited to the colon. This is intriguing in light of recent studies, which suggest the requirement for induction of Tregs in the small intestine in order to prevent colitis in the dextran sulfate sodium (DSS) and CD4<sup>+</sup> transfer models of colitis.<sup>32, 33</sup> In addition, the development of Th17 cells has also been shown to be regulated in the small intestine, further implicating the small intestine as a vital site of T helper cell development, particularly in the FVB.*mdr1a*<sup>-/-</sup>, where IL-17 plays a prominent role in colonic inflammation.<sup>43</sup>

While there appear to be fewer Tregs present in the FVB.*mdr1a*<sup>-/-</sup> small intestine, these Tregs can suppress Teff proliferation *in vitro*, although not quite as effectively as wild type Tregs. In addition, the FVB Tregs can suppress TNF- $\alpha$  secretion to a significant level, the FVB.*mdr1a*<sup>-/-</sup> Tregs cannot. These two findings indicate that even the Tregs that do get to the colon may not function effectively. Our findings are particularly interesting as it is now clear that in many patients, anti-TNF- $\alpha$  therapies are very effective in the treatment of IBD. These anti-TNF- $\alpha$  antibodies might be filling a potential void left by defective Tregs in human IBD patients. It has even been reported that anti-TNF- $\alpha$  therapy increases the number and efficacy of Tregs in IBD patients.<sup>44</sup> This data should warrant further

investigation of the interactions between Tregs and TNF- $\alpha$  in IBD, particularly in patients on anti-TNF- $\alpha$  therapeutics.

P-gp has been shown to protect tumor and leukemia cell lines from caspase 3 mediated apoptosis, and a loss of P-gp could make a cell more susceptible to apoptosis.<sup>4, 5</sup> Interestingly, when this was tested in the FVB.*mdr1a*<sup>-/-</sup> mice, there was no difference in activated caspase 3 expression on Foxp3<sup>+</sup> Tregs, and no difference was observed in Fas/Fas ligand mediated apoptosis, except in the MLN. While we cannot rule out that this slightly increased apoptosis of Foxp3<sup>+</sup> cells in the MLN contributes to the decreased numbers of Tregs in the small intestine, we do not believe the magnitude of this increase is enough to explain the dramatic loss of Tregs in the intestine. In addition, several recent studies have shown that activating caspase 3 may actually increase relative Treg numbers in various disease models, including colitis.<sup>45, 46</sup> Altered trafficking of Tregs could also explain why fewer Foxp3<sup>+</sup> cells were present in the intestinal tissues of FVB.*mdr1a*<sup>-/-</sup> mice, but no difference was observed in  $\alpha_4\beta_7$ , CCR9 or CD103 expression in most cases. The increases in CCR6 in the intestine most likely indicate the presence of an increased number of cells which have encountered antigen.<sup>47</sup> While our experiments involving trafficking are not exhaustive, the data does suggest that common trafficking mechanisms are not responsible for the decreased Foxp3<sup>+</sup> cells. In addition, this data indicates that blocking  $\alpha_4\beta_7$  to inhibit effector T cell migration and intestinal inflammation, may also prevent movement of regulatory T cells into the intestine to control disease.<sup>48</sup> This may especially true in patients with the *MDR1* polymorphisms, as small intestinal CD4<sup>+</sup>Foxp3<sup>+</sup> LP cells have increased levels of  $\alpha_4\beta_7$ , indicating this is an important molecule for Treg trafficking to the gut.

Because increased apoptosis or altered Treg trafficking did not appear to be the cause of reduced intestinal Tregs, we further explored the possibility that there was altered Treg plasticity by testing for the presence of IFN- $\gamma$  and IL-17 producing Foxp3<sup>+</sup> cells from spleen, MLN, PP, and intestinal LP. It has recently been shown that Foxp3<sup>+</sup> cells are capable of secreting proinflammatory cytokines.<sup>37</sup> In addition, it has been demonstrated in a model of type 1 diabetes that Foxp3<sup>+</sup> cells can express ROR $\gamma$ t and secrete IL-17, while in a model of colitis, Foxp3<sup>+</sup> cells have been shown to switch to an IFN- $\gamma$  secreting Th1 phenotype in the presence of IL-12 *in vitro*.<sup>35, 36</sup> These recent studies describing Treg plasticity suggested FVB.*mdr1a*<sup>-/-</sup> Tregs might be shifting to a Th1 or Th17 phenotype in an inflammatory setting. Surprisingly, no difference was observed in the Foxp3<sup>+</sup>INF- $\gamma$ <sup>+</sup> or the Foxp3<sup>+</sup>IL-17<sup>+</sup> populations when freshly isolated from FVB and FVB.*mdr1a*<sup>-/-</sup> animals. Although double positive cells were detected, particularly in the small intestine, FVB and FVB.*mdr1a*<sup>-/-</sup> had similar percentages, thus suggesting that altered Treg plasticity probably is not the cause of lower Treg percentages in the FVB.*mdr1a*<sup>-/-</sup> intestine.

While it does not appear that Foxp3<sup>+</sup> cells are shifting to a proinflammatory phenotype, it is possible that the generation of Tregs, particularly iTregs, may be altered, especially in this intestinal environment, which is known to have increased intestinal permeability and increased pro-inflammatory cytokines in the intestine prior to inflammation.<sup>31, 42</sup> This inflammatory environment is known to include IL-6, which can shift T cells away from iTreg to a Th17 cell.<sup>38</sup> To examine the generation of iTregs, purified CD4<sup>+</sup>CD25<sup>-</sup> or CD4<sup>+</sup>CD25<sup>+</sup> cells were treated with IL-6, TGF- $\beta$ , or IL-6 and TGF- $\beta$ . TGF- $\beta$  is a cytokine known to induce Foxp3 expression and promote iTreg development, so the failure of TGF- $\beta$  to induce Foxp3 expression in FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells was particularly surprising.<sup>15</sup> To determine if this failure to induce iTregs was also true *in vivo*, we have demonstrated that FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells were less able to convert to Foxp3<sup>+</sup> iTregs in an adoptive transfer model. While it is possible that the presence of Foxp3<sup>+</sup> cells in the spleen and MLN is a result of the small contaminating Foxp3<sup>+</sup> population (0.3%) proliferating and expanding, we do not believe this explains our results. We have observed

that FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>+</sup> cells demonstrate higher levels of proliferation to *in vitro* stimulation than FVB CD4<sup>+</sup>CD25<sup>+</sup> cells, which would imply that if proliferation and expansion of this donor Foxp3<sup>+</sup> population was responsible for the *in vivo* presence of CD4<sup>+</sup>Foxp3<sup>+</sup> cells in this transfer model, there should be more FVB.*mdr1a*<sup>-/-</sup> cells rather than less cells, as observed.

Taken together, this data would suggest that P-gp deficient T cells are less able to be instructed to become iTregs. Although the mechanism for this inefficient Treg induction is unclear, one possibility can be found based on the knowledge that the normal balance between iTreg and Th17 induction in the presence of TGF- $\beta$  is tipped towards Th17 by the presence of IL-6.<sup>49</sup> It is known that one downstream effect of IL-6 is a dramatic decrease in P-gp expression.<sup>50, 51</sup> We propose that this downregulation is a required step for differentiation into a Th17 cell and blocks efficient differentiation into Tregs. This hypothesis is consistent with our results, as in our mice where P-gp expression is already absent, there is enhanced production of IL-17 and inhibited development of iTregs, even in the absence of IL-6. This hypothesis is also consistent with our observation that CD4<sup>+</sup>CD25<sup>+</sup> Tregs have increased gene and functional expression of P-gp. We would propose that it is the small percentage of CD4<sup>+</sup>CD25<sup>-</sup> cells that already express P-gp that are most susceptible to iTreg induction. Definitive experimental testing of this proposal awaits better cell surface markers for P-gp that can be used to sort out the P-gp expressing subsets that would be required. Because it has been shown that both iTregs and nTregs are vital in maintaining immune homeostasis in the intestines, this defect in iTreg generation could certainly be contributing to the inflammation in FVB.*mdr1a*<sup>-/-</sup> mice.<sup>25</sup>

This study has explored the role of Tregs in the FVB.*mdr1a*<sup>-/-</sup> mouse model of colitis, and determined that decreased levels of Tregs, specifically iTregs, is a result of altered T cell lineage commitment. A deficiency in P-gp seems to prevent iTregs from being induced, particularly in mucosal compartments where iTregs are known to be a significant component of the total Treg population.<sup>52</sup> This information has a direct impact on the human population, as polymorphisms in the human homologue of murine *mdr1a*, *MDR1*, have been linked to inflammatory bowel disease.<sup>12-14</sup> The role of iTregs in *MDR1* IBD patients has yet to be explored, and could provide vital information on the best way to treat patients with *MDR1* specific polymorphisms. The generation of Tregs *ex vivo* for transfer back into patients has been explored for the treatment of autoimmune diseases, including IBD. Our data would suggest that it may be difficult to generate these cells from the patients themselves, depending on the mutation that a given patient may have. Tregs in IBD remain a mystery, as Tregs are decreased in peripheral blood, yet appear to have normal cell-contact function when isolated from the colon of patients with active disease.<sup>26</sup> This suggests there may be alternative Treg functional defects in IBD patients, possibly similar to what we now describe in the FVB.*mdr1a*<sup>-/-</sup> model. In addition, this information may prove the importance of how patients with various mutations resulting in IBD are treated, and specific treatments based on the polymorphisms may provide more effective medical care in the future.

## METHODS

### Animals

FVB/N and FVB.129P2-*Abcb1<sup>tm1Bor</sup>N7* (FVB.*mdr1a*<sup>-/-</sup>) as originally described by Schinkel *et al* were purchased from Taconic Farms (Hudson, NY). FVB.*Rag2*<sup>-/-</sup> mice were a gift from Dr. Benjamin E. Rich, Harvard Skin Diseases Research Center, Brigham and Women's Hospital Department of Dermatology. Unless otherwise noted, all animals used in this study were males, 6–8 weeks of age. Animals were bred and maintained under specific pathogen-free (SPF) conditions in Thoren Isolator racks (Hazleton, PA) under positive



pressure. The Institutional Care and Use Committee of the University of Alabama at Birmingham (UAB) approved all experiments. SPF conditions at UAB include absence of the following organisms, as determined by serological screening: mouse parvoviruses, including MPV-1, MPV-2, and minute virus of mice; mouse hepatitis virus, murine norovirus, Theiler's murine encephalomyelitis virus; mouse rotavirus (epizootic diarrhea of infant mice), Sendai virus; pneumonia virus of mice; reovirus; *Mycoplasma pulmonis*; lymphocytic choriomeningitis virus; mouse adenovirus; ectromelia (mousepox) virus; K polyoma virus; and mouse polyoma virus. Testing and other methods were as described at <http://main.uab.edu/Sites/ComparativePathology/surveillance/>.

### Cell Isolation

Spleen, mesenteric lymph nodes (MLN), and Peyer's patches (PP) were removed and cells isolated via single cell suspension by mechanical disruption. To isolate intestinal lamina propria (LP), small intestines and colons were removed, sliced open, and washed several times in HBSS supplemented with 2% newborn calf serum (HyClone, Logan, UT), L-glutamine (Mediatech, Manassas, VA), penicillin/streptomycin (Mediatech), and 2-mercaptoethanol (Sigma-Aldrich, St. Louis, MO). Intestines were then incubated with 0.2mM EDTA and 0.15mg/ml dithiothreitol (DTT, Fisher Scientific, Pittsburgh, PA) with gentle shaking at 37°C for 40 minutes (epithelial cells and intraepithelial lymphocytes were discarded), followed by incubation with 1mg/ml collagenase type IV (Sigma-Aldrich) and 20µg/ml DNase I (Roche, Indianapolis, IN) with stirring at 37°C for 40 minutes. Cells were then filtered through a 100µm stainless steel wire filter and collected at the interface of a 40%/75% Percoll gradient. For some experiments, small intestine and colon (excluding cecum) were prepped and analyzed separately. All cells were rested for 18 hours in RPMI supplemented with 10% fetal calf serum at 4°C.

### Flow Cytometry

Cells were stained for both extracellular and intracellular molecules using the eBioscience Foxp3 Staining Buffer Set (eBioscience, San, Diego, CA). In summary, Fc receptors on target cells were blocked incubating with anti-CD16/CD32 (1 µg/sample) for 15 minutes at 4°C. Cells were washed and stained with all extracellular antibodies for 30 minutes at 4°C. Cells were washed and incubated with 100µl of eBioscience Permeabilization/Fixation Solution for 30 minutes at 4°C. Cells were washed and stained with intracellular antibodies for 30 minutes at 4°C. Cells were then washed and resuspended in 1% paraformaldehyde solution in 0.15M NaCl<sub>2</sub> until analysis. If cells were being stained for cytokine production, cells were incubated at 37°C for 5 hours in the presence of 50 ng/ml phorbol 12-myristate 13-acetate, 750 ng/ml ionomycin, and GolgiStop (BD Biosciences). Antibodies used: Fluorescein isothiocyanate (FITC) conjugated CD4 (clone L3T4, BD Biosciences, San Jose, CA), PerCP-Cy5.5 conjugated CD4 (clone RM4-5, BioLegend), Phycoerythrin (PE) conjugated CD25 (clonePC61, BD Biosciences), PE conjugated CD103 (clone M290, BD Bioscience), PE conjugated CCR9 (clone 242503, R&D Systems, Minneapolis, MN), Allophycocyanin (APC) conjugated Foxp3 (clone FKJ-16s, eBioscience), PE conjugated LPAM-1 (α<sub>4</sub>β<sub>7</sub>) (clone DATK32, BD Biosciences), FITC conjugated INF-γ (clone XMG1.2, BioLegend), PE conjugated IL-17A (clone TC11-18H10, BD Biosciences). All flow cytometry was done on a Becton Dickinson FACSCalibur (BD Biosciences) and events collected using CellQuest software. All analysis was done utilizing FlowJo software (Tree Star, Inc., Ashland, OR).

### Cell Separation

CD4<sup>+</sup>CD25<sup>-</sup> and CD4<sup>+</sup>CD25<sup>+</sup> cells were isolated by magnetic bead separation using the MACS CD4<sup>+</sup>CD25<sup>+</sup> Cell Isolation Kit (Miltenyi Biotech, Auburn, CA) and following the manufacturer's protocol. Briefly, CD4<sup>+</sup> cells were first isolated by negative selection.

CD25<sup>+</sup> cells were then selected for by positive selection, allowing separation of the CD25<sup>-</sup> and CD25<sup>+</sup> fractions. After isolation, CD4<sup>+</sup>CD25<sup>+</sup> fraction contained approximately 80% CD4<sup>+</sup>Foxp3<sup>+</sup> cells (Supplementary Figure S1).

### RNA Isolation and RT-PCR

RNA was obtained from fresh MACS isolated cells using the QIAGEN RNeasy RNA extraction kit (QIAGEN Inc.; Valencia, CA). cDNA was synthesized using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Pensburg, Germany). Quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR) was performed using TaqMan Universal PCR Mix (Invitrogen, Grand Island, NY) in combination with Applied Biosystems TaqMan Gene Expression Assay primer probe sets (Applied Biosystems, Carlsbad, CA) for *Abcb1a* (Applied Biosystems Assay ID Mm00440761\_m1). RNA expression level was calculated using the crossing threshold of detectable fluorescence level as determined by the RT cycler MX3000P (Stratagene, La Jolla, CA). Crossing thresholds were then averaged to get a gene-specific value that was then normalized to the average expression of the 18S housekeeping gene for each strain and experimental condition studied. The 18S housekeeping gene was utilized as the housekeeping gene in this study as published results indicate it is expressed with relative stability under inflammatory conditions.<sup>53-55</sup>

### Rhodamine-123 Flux Assay

To measure P-gp activity, the rhodamine-123 (R-123) flux assay was modified from protocols previously described by Chaudhary *et al.*<sup>7, 34</sup> Freshly isolated cells were incubated with 100 ng/ml R-123 (Invitrogen) for 1 hour at 4°C. Cells were then washed, and incubated with R-123 free media for 1–4 hours at 4°C (Loaded control) or 37°C (Flux). Cells were then stained for appropriate surface molecules and analyzed immediately via flow cytometry.

### Cell Proliferation Assay

FVB CD4<sup>+</sup>CD25<sup>-</sup> and FVB or FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>+</sup> freshly isolated via MACS as described above were cultured alone at 2×10<sup>6</sup> cells/ml, or co-cultured in 200µl RPMI supplemented with 10% fetal calf serum, penicillin/streptomycin (Mediatech), L-glutamine (Mediatech), and 2-mercaptoethanol (Sigma-Aldrich) in a 96 well plate coated with 1 µg/ml anti-CD3 (BD Biosciences) and 0.5 µg/ml anti-CD28 (BD Biosciences) for 96 hours total. Supernatants for ELISA and multiplex suspension cytokine array were collected after 72 hours of culture and media replaced. 1 µCi <sup>3</sup>H-Thymidine (Perkin-Elmer, Waltham, MA) added for final 24 hours of culture. <sup>3</sup>H-Thymidine incorporation was quantitated by harvesting cells on a Perkin-Elmer Filtermate Unifilter-96 Harvester and analyzing on a Perkin-Elmer TopCount NXT scintillation counter using TopCount NXT software.

### Apoptosis Assays

To test for the presence of apoptotic (activated caspase-3<sup>+</sup>) Foxp3<sup>+</sup> cells in the intestine, immunohistochemical techniques were used as previously described<sup>56</sup>. Briefly, tissue was isolated and placed in cassettes. Tissue was then immersion fixed in cold 4°C Bouin's solution (Fisher Scientific; Pittsburg, PA) overnight at 4°C, then changed to ethanol, and embedded in paraffin. The tissue was cut into 5-3m sections on a microtome and attached to precleaned microscope slides (Snowcoat X-tra; Surgipath, Richmond, IL). To visualize Foxp3<sup>+</sup> and activated caspase-3<sup>+</sup> cells within the tissue, slides were deparaffinized with CitriSolv (Fisher Scientific, Pittsburgh, PA) followed by isopropanol, rinsed with DI water, and rehydrated with PBS. Endogenous peroxidase was blocked by adding 3% H<sub>2</sub>O<sub>2</sub> to the slides for 10 minutes and washing the slides with DI water. Avidin- and biotin- blocking reagents (Avidin-Biotin Blocking Kit; Vector Laboratories, Burlingame, CA) were

sequentially incubated on the slides for 15 minutes at room temperature in a humidity chamber. Slides were washed with PBS after each blocking solution. Slides were incubated at room temperature for 15 minutes with PBS supplemented with 1% BSA, 0.2% powdered milk, and 0.3% Triton X-100 (Blocking Solution), then the 10 µg/ml biotinylated Foxp3 (clone FKJ-16s, eBioscience) primary antibody diluted in PBS-BB to 10 µg/ml was added, and the slides were incubated overnight at 4°C. After washing slides in PBS, 2.5 µg/ml streptavidin-HRP (Jackson ImmunoResearch, West Grove, PA, diluted in Blocking Solution) was incubated on the slide for 30 minutes at room temperature. Slides were then incubated with FITC Tyramide Amplification Reagent (Perkin Elmer) for 30 minutes at room temperature in the dark per the manufacturer's protocol. Remaining peroxidase was then blocked by repeating the incubation with H<sub>2</sub>O<sub>2</sub> for 10 minutes, then the activated caspase 3 (clone D175, Cell Signaling Technologies) primary antibody (diluted 1:250 in Blocking Solution) was added, and the slides were incubated overnight at 4°C. After washing slides in PBS, 2.5 µg/ml donkey anti-rabbit-HRP (Jackson ImmunoResearch) was diluted in Blocking Solution and incubated on the slide for 30 minutes at room temperature. Slides were then incubated with Cy3 Tyramide Amplification Reagent (Perkin Elmer) for 30 minutes at room temperature in the dark per the manufacturer's protocol. This dual TSA staining protocol is performed as previously described<sup>57</sup>. After a PBS rinse, slides were counterstained with Hoechst (33342, Sigma) to label nuclei. Tissue was visualized using a Zeiss AxioScope and images were captured and analyzed using a Zeiss AxioCam with AxioVision 4.7 software (Carl Zeiss, Inc., Peabody, MA).

To investigate sensitivity to apoptosis induction, cells were isolated from spleen, MLN, PP, and LP as described above.  $1 \times 10^6$  cells were then incubated in a round-bottom 96-well plate for 18 hours in the presence of 10 µg/ml anti-CD95 (clone Jo2, BD Biosciences). Cells were then stained for flow cytometry as described above.

### Cytokine Measurements

ELISAs were performed to measure levels of IL-10, IL-17A and IFN-γ. Briefly, Immulon 96 well plates were coated with capture antibody (4.0 µg/ml IL-10: clone JES5-2A5, 1 µg/ml IL-17A: clone TC11-18H10.1, 0.5 µg/ml IFN-γ: clone R4-6A2) overnight at 4°C. Plates were then washed and blocked with PBS containing 10% newborn calf serum. Plates were again washed and culture supernatant or known standard was added for 2 hours at room temperature. Standard consisted of 7 dilutions and a blank, run in triplicate. Dilutions started at 5 µg/ml IL-10, 2.5 µg/ml IL-17, and 5 µg/ml INF-γ, and were diluted 1:2. Samples were washed off and the biotinylated detection antibody (0.75 µg/ml IL-10: clone JES5-16E3, 0.5 µg/ml IL-17A: clone TC11-8H4, IFN-γ: clone 1 µg/ml XMG1.2) was added for 1 hour at room temperature. Plates were washed again, and streptavidin-horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA) was added for 30 minutes. Plates were washed for a final time, and 3,3',5,5'-tetramethylbenzidine (Thermo Scientific, Rockford, IL) was added and developed for 15 minutes (IL-17A and IFN-γ) or 30 minutes (IL-10). The reaction was stopped by adding H<sub>2</sub>SO<sub>4</sub> and the plates were read on a VERSAmax microplate reader (Molecular Devices, Sunnyvale, CA) at 450 nm. All capture and detection antibodies were purchased from BioLegend (San Diego, CA).

Multiplex analysis of cell culture supernatants was done to measure levels of IFN-γ, IL-2, IL-10, IL-17A, and TNF-α using a Luminex-based Bio-Plex multiplex suspension protein assay (Bio-Rad, Hercules, CA) Bio-Plex Assay kit following the manufacturer's protocol.

### Chemotaxis Assay

The T cell chemokine receptor activation and chemotaxis assay was performed as previously described.<sup>58</sup> Because cell activation increases CD4<sup>+</sup> cell chemotaxis, cells were isolated and

stimulated prior to the chemotaxis analysis. CD4<sup>+</sup> lymphocytes were isolated from spleens using the BD CD4<sup>+</sup> T Lymphocyte Enrichment Kit (BD Biosciences) following the manufacturer's protocol. Cells were then plated at  $5 \times 10^5$  cells/well in 200  $\mu$ l RPMI supplemented with 10% fetal calf serum, penicillin/streptomycin (Mediatech), L-glutamine (Mediatech), 2-mercaptoethanol (Sigma-Aldrich) and 10 ng/ml recombinant mouse IL-2 (BioLegend) in a 96 well plate coated with 1  $\mu$ g/ml anti-CD3 (BD Biosciences) and 0.5  $\mu$ g/ml anti-CD28 (BD Biosciences) and cultured for 48 hours at 37°C. Cells were then rested in a plate with no CD3/CD28 stimulation with fresh media and IL-2 for 48 hours at 37°C. After resting, the cells were washed, counted, and the CD4<sup>+</sup>CD25<sup>+</sup> population was isolated using the MACS CD4<sup>+</sup>CD25<sup>+</sup> Cell Isolation Kit (Miltenyi Biotec), following the manufacturer's protocol.

Once isolated, the cells were rested for 1 hour at 37°C to recover from isolation. The each well of the upper chamber of the 3.0  $\mu$ m transwell (Millipore, Billerica, MA) was coated with 50  $\mu$ l of 10  $\mu$ g/ml bovine plasma fibronectin (Sigma-Aldrich) for 1 hour at 37°C. Fibronectin was then removed, and upper chambers air dried for 30 minutes at room temperature. 150  $\mu$ l of chemokine mixture (various concentrations of chemokines used, from 1–100 ng/ml) in RPMI supplemented with 0.5% fetal bovine serum was placed in the bottom chamber.  $5 \times 10^5$  cells in 50  $\mu$ l of RPMI supplemented with 0.5% fetal bovine serum were placed in the upper chambers. Plates were incubated for 3 hours at 37°C. Upper chambers were removed, and migrated cells in the bottom wells were counted by hemocytometer to determine the number of cells migrated.

### Cell Culture

To investigate Treg plasticity and iTreg induction, splenic CD4<sup>+</sup>CD25<sup>-</sup> and CD4<sup>+</sup>CD25<sup>+</sup> cells were isolated and separated as described above.  $3 \times 10^5$  freshly separated cells were then added to a 96-well flat-bottom plate coated with anti-CD3 (1  $\mu$ g/ml) and anti-CD28 (0.5  $\mu$ g/ml) for 72 hours at 37°C in media alone, or in the presence of 5 ng/ml recombinant human TGF- $\beta$ , 25 ng/ml recombinant mouse IL-6, or 10 ng/ml recombinant mouse IL-1 $\beta$  (or combinations of those cytokines). After 72 hours, cells were rested in fresh media for 24 hours, and then stained as described above. All cytokines purchased from BioLegend.

### Adoptive Transfer

To test the in vivo capability of FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells to become iTregs, adoptive transfer experiments were performed as previously described.<sup>59</sup> Cells for adoptive transfer were obtained from 6–8 week old FVB and FVB.*mdr1a*<sup>-/-</sup> spleens as described above. Once in single cell suspension, the cells were stained for CD4 and CD25 as described above. CD4<sup>+</sup>CD25<sup>-</sup> cells were then sorted using a BD Biosciences FACSaria cell sorter (BD Biosciences), obtaining 98–99% purity of the CD4<sup>+</sup>CD25<sup>-</sup> population. After sorting, cells were washed and resuspended in PBS, and  $1 \times 10^6$  CD4<sup>+</sup>CD25<sup>-</sup> cells were delivered in a volume of 100  $\mu$ l PBS by intraperitoneal injection into 6–8 week old FVB.*Rag2*<sup>-/-</sup> recipients. After 14 days, the recipient mice were sacrificed, and the spleen, MLN, and intestinal lamina propria was isolated as described above. The cells were then stained for CD4, CD25, and Foxp3 and analyzed as described above.

### Statistical Analysis

Statistics on continuous data was performed using the unpaired *t*-test in GraphPad Prism software (San Diego, CA). *P* values  $\leq 0.05$  are shown.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

The authors would like to thank A. Metz and C. Steele for assistance with multiplex analysis, and E. Keyser with the UAB Rheumatic Diseases Analytic and Preparative Cytometry Facility (NIH 5P30 AR048311) for FACS sorting assistance. We would also like to thank J. McNaught for slide preparation and M. Harris for animal husbandry, and members of the Lorenz lab for valuable advice. This study was supported in part by NIH grants R01 DK059911; P01 DK071176; and University of Alabama at Birmingham Digestive Diseases Research Development Center grant P30 DK064400. SMT is supported by the Howard Hughes Medical Institute Med into Grad Fellowship and the University of Alabama at Birmingham Carmichael Fund. Aspects of this project were conducted in biomedical research space that was constructed with funds supported in part by NIH grant C06RR020136.

## References


1. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, *mdr1a*, spontaneously develop colitis. *J Immunol.* 1998; 161:5733–5744. [PubMed: 9820555]
2. Maggio-Price L, et al. Dual infection with *Helicobacter bilis* and *Helicobacter hepaticus* in p-glycoprotein-deficient *mdr1a*<sup>-/-</sup> mice results in colitis that progresses to dysplasia. *Am J Pathol.* 2005; 166:1793–1806. [PubMed: 15920164]
3. Schinkel AH, et al. Disruption of the mouse *mdr1a* P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. *Cell.* 1994; 77:491–502. [PubMed: 7910522]
4. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. *Proc Natl Acad Sci U S A.* 1998; 95:7024–7029. [PubMed: 9618532]
5. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. *Blood.* 1999; 93:1075–1085. [PubMed: 9920858]
6. Drach D, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. *Blood.* 1992; 80:2729–2734. [PubMed: 1360266]
7. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. *Blood.* 1992; 80:2735–2739. [PubMed: 1360267]
8. Coon JS, et al. Multidrug resistance activity in human lymphocytes. *Hum Immunol.* 1991; 32:134–140. [PubMed: 1720770]
9. Randolph GJ, et al. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. *Proc Natl Acad Sci U S A.* 1998; 95:6924–6929. [PubMed: 9618515]
10. van de Ven R, Scheffer GL, Scheper RJ, de Gruijl TD. The ABC of dendritic cell development and function. *Trends Immunol.* 2009; 30:421–429. [PubMed: 19699682]
11. Staley EM, Dimmitt RA, Schoeb TR, Tanner SM, Lorenz RG. Critical Role For P-Glycoprotein Expression in Hematopoietic Cells In The Fvb.*Mdr1a*<sup>-/-</sup> Model of Colitis. *J Pediatr Gastroenterol Nutr.* 2011
12. Annese V, et al. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. *World J Gastroenterol.* 2006; 12:3636–3644. [PubMed: 16773678]
13. Onnie CM, et al. Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study. *Inflamm Bowel Dis.* 2006; 12:263–271. [PubMed: 16633048]
14. Ho GT, et al. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. *Hum Mol Genet.* 2006; 15:797–805. [PubMed: 16434479]
15. Chen W, et al. Conversion of peripheral CD4<sup>+</sup>CD25<sup>-</sup> naive T cells to CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J Exp Med.* 2003; 198:1875–1886. [PubMed: 14676299]




16. Razmara M, Hilliard B, Ziarani AK, Chen YH, Tykocinski ML. CTLA-4 x Ig converts naive CD4+CD25- T cells into CD4+CD25+ regulatory T cells. *Int Immunol.* 2008; 20:471–483. [PubMed: 18272926]
17. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? *Int Immunol.* 2009; 21:1105–1111. [PubMed: 19737784]
18. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science.* 2003; 299:1057–1061. [PubMed: 12522256]
19. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol.* 2003; 4:330–336. [PubMed: 12612578]
20. Fantini MC, et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. *J Immunol.* 2004; 172:5149–5153. [PubMed: 15100250]
21. Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF- $\beta$ . *J Immunol.* 2005; 174:1446–1455. [PubMed: 15661903]
22. Coombes JL, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. *J Exp Med.* 2007; 204:1757–1764. [PubMed: 17620361]
23. Sun CM, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. *J Exp Med.* 2007; 204:1775–1785. [PubMed: 17620362]
24. Cong Y, Weaver CT, Lazenby A, Elson CO. Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. *J Immunol.* 2002; 169:6112–6119. [PubMed: 12444113]
25. Haribhai D, et al. A central role for induced regulatory T cells in tolerance induction in experimental colitis. *J Immunol.* 2009; 182:3461–3468. [PubMed: 19265124]
26. Holmén N, et al. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. *Inflamm Bowel Dis.* 2006; 12:447–456. [PubMed: 16775488]
27. Makita S, et al. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. *J Immunol.* 2004; 173:3119–3130. [PubMed: 15322172]
28. Saruta M, et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. *Clin Immunol.* 2007; 125:281–290. [PubMed: 17897887]
29. Fedorak RN, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. *Gastroenterology.* 2000; 119:1473–1482. [PubMed: 11113068]
30. Schreiber S, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. *Gastroenterology.* 2000; 119:1461–1472. [PubMed: 11113067]
31. Staley EM, Schoeb TR, Lorenz RG. Differential susceptibility of P-glycoprotein deficient mice to colitis induction by environmental insults. *Inflamm Bowel Dis.* 2009; 15:684–696. [PubMed: 19067430]
32. Fujiwara D, Chen L, Wei B, Braun J. Small intestine CD11c+ CD8+ T cells suppress CD4+ T cell-induced immune colitis. *Am J Physiol Gastrointest Liver Physiol.* 2011; 300:G939–947. [PubMed: 21436315]
33. McFarland AP, et al. Localized delivery of interferon- $\beta$  by *Lactobacillus* exacerbates experimental colitis. *PLoS One.* 2011; 6:e16967. [PubMed: 21365015]
34. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. *Cell.* 1991; 66:85–94. [PubMed: 1712673]
35. Tartar DM, et al. FoxP3+RORgammat+ T helper intermediates display suppressive function against autoimmune diabetes. *J Immunol.* 2010; 184:3377–3385. [PubMed: 20181889]
36. Feng T, Cao AT, Weaver CT, Elson CO, Cong Y. Interleukin-12 converts Foxp3+ regulatory T cells to interferon- $\gamma$ -producing Foxp3+ T cells that inhibit colitis. *Gastroenterology.* 2011; 140:2031–2043. [PubMed: 21419767]

37. Zhou X, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. *Nat Immunol.* 2009; 10:1000–1007. [PubMed: 19633673]
38. Lee YK, Mukasa R, Hatton RD, Weaver CT. Developmental plasticity of Th17 and Treg cells. *Curr Opin Immunol.* 2009; 21:274–280. [PubMed: 19524429]
39. Thornton AM, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. *J Immunol.* 2010; 184:3433–3441. [PubMed: 20181882]
40. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. *J Immunol.* 2012; 188:976–980. [PubMed: 22198953]
41. Collett A, et al. Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in *mdr1a(-/-)* mice. *Inflamm Bowel Dis.* 2008; 14:620–631. [PubMed: 18275070]
42. Resta-Lenert S, Smitham J, Barrett KE. Epithelial dysfunction associated with the development of colitis in conventionally housed *mdr1a(-/-)* mice. *Am J Physiol Gastrointest Liver Physiol.* 2005; 289:G153–162. [PubMed: 15774938]
43. Esplugues E, et al. Control of TH17 cells occurs in the small intestine. *Nature.* 2011; 475:514–518. [PubMed: 21765430]
44. Boschetti G, et al. Therapy with anti-TNF $\alpha$  antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. *Inflamm Bowel Dis.* 2011; 17:160–170. [PubMed: 20848510]
45. Yarkoni S, Sagiv Y, Kaminitz A, Farkas DL, Askenasy N. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis. *Eur J Immunol.* 2009; 39:2850–2864. [PubMed: 19735074]
46. Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. *J Immunol.* 2011; 187:2015–2022. [PubMed: 21742976]
47. Kleinewietfeld M, et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. *Blood.* 2005; 105:2877–2886. [PubMed: 15613550]
48. Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. *Therap Adv Gastroenterol.* 2010; 3:239–258.
49. Korn T, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. *Proc Natl Acad Sci U S A.* 2008; 105:18460–18465. [PubMed: 19015529]
50. Sukhai M, Yong A, Kalitsky J, Piquette-Miller M. Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the *mdr1a* and *mdr1b* Genes. *Mol Cell Biol Res Commun.* 2000; 4:248–256. [PubMed: 11409920]
51. Sukhai M, Yong A, Pak A, Piquette-Miller M. Decreased expression of P-glycoprotein in interleukin-1 $\beta$  and interleukin-6 treated rat hepatocytes. *Inflamm Res.* 2001; 50:362–370. [PubMed: 11506391]
52. Murai M, Krause P, Cheroutre H, Kronenberg M. Regulatory T-cell stability and plasticity in mucosal and systemic immune systems. *Mucosal Immunol.* 2010; 3:443–449. [PubMed: 20505662]
53. Bas A, Forsberg G, Hammarström S, Hammarström ML. Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. *Scand J Immunol.* 2004; 59:566–573. [PubMed: 15182252]
54. Ropenga A, Chapel A, Vandamme M, Griffiths NM. Use of reference gene expression in rat distal colon after radiation exposure: a caveat. *Radiat Res.* 2004; 161:597–602. [PubMed: 15161363]
55. Rubie C, et al. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. *Mol Cell Probes.* 2005; 19:101–109. [PubMed: 15680211]
56. Schmitz JM, Durham CG, Ho SB, Lorenz RG. Gastric mucus alterations associated with murine *Helicobacter* infection. *J Histochem Cytochem.* 2009; 57:457–467. [PubMed: 19153195]

57. Zaidi AU, Enomoto H, Milbrandt J, Roth KA. Dual fluorescent in situ hybridization and immunohistochemical detection with tyramide signal amplification. *J Histochem Cytochem.* 2000; 48:1369–1375. [PubMed: 10990490]
58. Siveke JT, Hamann A. T helper 1 and T helper 2 cells respond differentially to chemokines. *J Immunol.* 1998; 160:550–554. [PubMed: 9551886]
59. Shaw MH, Kamada N, Kim YG, Núñez G. Microbiota-induced IL-1 $\beta$ , but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. *J Exp Med.* 2012; 209:251–258. [PubMed: 22291094]




**Figure 1.** CD4<sup>+</sup>CD25<sup>+</sup> cells express P-glycoprotein and FVB.mdr1a<sup>-/-</sup> mice display a smaller percentage of CD4<sup>+</sup>Foxp3<sup>+</sup> Treg cells in intestinal lymphoid tissues. **(a)** Total cell lymphocyte counts after cell isolation. **(b)** Total percentage of CD4<sup>+</sup> and Foxp3<sup>+</sup>CD4<sup>+</sup> cells from FVB and FVB.mdr1a<sup>-/-</sup> spleen, MLN, Peyer’s patches (PP), and small intestinal (Sm. Int.) or colonic lamina propria (LP). Cells were collected from tissues and rested overnight prior to staining and flow cytometry. **(c)** Total cell numbers of CD4<sup>+</sup> or CD4<sup>+</sup>Foxp3<sup>+</sup> cells within each population. **(d)** RNA expression of Abcb1a (P-gp) in splenic CD4<sup>+</sup>CD25<sup>-</sup> (set as a relative value of 1.0), CD4<sup>+</sup>CD25<sup>+</sup>, and CD8<sup>+</sup> (known to express P-gp) splenocytes. **(e)** P-gp functional expression on CD4<sup>+</sup>CD25<sup>-</sup> and CD4<sup>+</sup>CD25<sup>+</sup> cells. MACS isolated cells were loaded with the P-gp specific substrate rhodamine-123 (R123) for 1 hour, followed by a 1 hour flux of R123. Shaded region represents loading control, while solid line indicates fluxed sample. Percentages indicate percent of cells fluxing R123 through P-gp activity. Small amount of flux is a result of free diffusion of R123 across cell membrane. Data are representative of 2 **(d)** or 3 **(a, b, and c)** separate experiments, with 3–4 male mice, 6–8 weeks of age in each group per experiment. \* *P* 0.05; \*\* *P* 0.01. Mean + standard deviation shown.




**Figure 2.** FVB.mdr1a<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>+</sup> Treg cells suppress CD4<sup>+</sup>CD25<sup>-</sup> Teff proliferation *in vitro*, but fail to suppress TNF- $\alpha$  secretion. (a) MACS isolated FVB CD4<sup>+</sup>CD25<sup>-</sup> (Teff) and CD4<sup>+</sup>CD25<sup>+</sup> (Treg) cells from either FVB or FVB.mdr1a<sup>-/-</sup> were cultured either separately or cultured together for 96 hours in the presence of anti-CD3 and anti-CD28. <sup>3</sup>H-Thymidine was added for the final 24 hours of culture. Assay was done at 1:1, 2:1, and 4:1 Teff:Treg ratio as indicated. (b) Supernatants from a were collected after 72 hours and prior to the addition <sup>3</sup>H-Thymidine. Cytokine concentrations were determined using multiplex kits. Data are representative of 3 separate experiments, with 3–4 male mice, 6–8 weeks of age in each




group per experiment. \*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ . Mean + standard deviation (**a**) or standard error of the mean (**b**) shown.




**Figure 3.** Intestinal FVB.mdr1a<sup>-/-</sup> Foxp3<sup>+</sup> cells do not have increased levels of apoptosis. (a) Sections of Peyer’s patches and (b) distal colon were stained for Foxp3 and cleaved caspase-3. Positive cells for stains are indicated by arrows in their respective panels. Images were captured at 40× magnification, and scale bars = 20 μm. (c) Cells were isolated from spleen, MLN, PP, and intestinal LP and stimulated for 18 hours with 10 μg/ml anti-CD95 to induce apoptosis. Cells were then stained for CD4, Foxp3 and cleaved caspase-3. Lymphocytes were gated based on forward scatter/side scatter. Cells were pre-gated on CD4<sup>+</sup> cells prior to analysis of Foxp3 and cleaved caspase 3 expression. Note that the high number of apoptotic cells in the LP may be a result of the extensive enzymatic digesting necessary to isolate these cells. Data are shown from one experiment, but are representative of 2 separate experiments, with 3–4 male mice, 6–8 weeks of age in each group per experiment. \* *P* 0.05; \*\* *P* 0.01; \*\*\* *P* 0.001. Mean + standard deviation shown.



**Figure 4.** Altered trafficking of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs does not account for the decreased levels of Tregs in the FVB.*mdr1a*<sup>-/-</sup> intestines. **(a)** Representative FACS histogram plots for  $\alpha_4\beta_7$ , CCR6, CCR9, and CD103 expression on CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in spleen, MLN, PP, small intestinal LP and colonic LP. Cells were isolated from tissues and rested overnight prior to staining. Lymphocytes were gated on based on forward scatter/side scatter and then subsequently gated on CD4<sup>+</sup>Foxp3<sup>+</sup> cells. Percentages shown are for only this representative FACS plot, shaded region = FVB, Solid line = FVB.*mdr1a*<sup>-/-</sup>. **(b)** Histograms representing the mean percentages (upper panels) and cell counts (lower panels) from analysis of each individual histogram gated on CD4<sup>+</sup>Foxp3<sup>+</sup> as represented in **a**. Data shown are the means from one representative experiment, which was repeated twice. Each experiment individually analyzed, 3–4 male mice, 6–8 weeks of age. \* *P* 0.05; \*\* *P* 0.01; \*\*\* *P* 0.001. Mean + standard deviation shown.




**Figure 5.** FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>Foxp3<sup>+</sup> cells do not have higher co-expression of IFN- $\gamma$  or IL-17 in the intestines. **(a)** Representative FACS plots of Foxp3 vs IFN- $\gamma$  or Foxp3 vs IL-17A in spleen, MLN, PP, small intestinal LP, and colonic LP. Cells were isolated from tissues and rested overnight prior to stimulation with PMA and ionomycin in the presence of monensin. Cells were then stained for CD4, Foxp3, IFN- $\gamma$  and IL-17. Lymphocytes were gated on based on forward scatter/side scatter and subsequently gated on CD4<sup>+</sup> cells. **(b)** Dot plots representing the individual mice and the mean from one representative experiment. Data was reproduced in 3 separate experiments with 3 mice male mice (6–8 weeks of age) per group. Mean + standard deviation shown.



**Figure 6.** FVB.*mdr1a*<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells do not become Foxp3<sup>+</sup> cells upon treatment with TGF-β and are more likely to become Foxp3<sup>+</sup>IL-17<sup>+</sup> cells. **(a)** MACS isolated CD4<sup>+</sup>CD25<sup>-</sup> (upper panels) and CD4<sup>+</sup>CD25<sup>+</sup> (lower panels) cells were cultured for 72 hours with CD3 and CD28 stimulation in the presence of 25 ng/ml IL-6 alone, 5 ng/ml TGF-β alone, or IL-6 and TGF-β together. Cells were rested for 24 hours, then subsequently stained for CD4, Foxp3, and IL-17. **(b)** Supernatants from **a** were collected after 72 hours of culture and analyzed for IL-10, IL-17, and IFN-γ secretion by ELISA. It is important to note that freshly isolated splenic CD4<sup>+</sup>Foxp3<sup>-</sup> (and CD4<sup>+</sup>Foxp3<sup>+</sup>) cells from FVB and FVB.*mdr1a*<sup>-/-</sup> express similar levels of the activation markers CD44, CD62L, and CD69, indicating that the activation states of these cells is the same (data not shown). Results are representative of 2 independent experiments, with 3–4 male mice, 6–8 weeks of age in each group per experiment. N.D. = not detected (below detectable level of assay). \* *P* 0.05; \*\* *P* 0.01; \*\*\* *P* 0.001. Mean of 3–4 mice (analyzed separately) + standard deviation shown.





**Figure 7.** FVB.mdr1a<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells show impaired Foxp3<sup>+</sup> iTreg generation *in vivo*. **(a)** An schematic of the adoptive transfer experiment. Splenocytes from FVB and FVB.mdr1a<sup>-/-</sup> mice were stained for CD4 and CD25, and subsequently isolated via FACS cell sorting. Representative pre-sort (left panels) and post-sort (right panels) are shown for both FVB and FVB.mdr1a<sup>-/-</sup>. 1×10<sup>6</sup> CD4<sup>+</sup>CD25<sup>-</sup> cells were then injected i.p. into FVB.Rag2<sup>-/-</sup> recipients. After 14 days, the spleen, MLN and intestinal lamina propria was harvested from the recipients. **(b)** Foxp3<sup>+</sup> expression on the gated CD4<sup>+</sup> population of spleen and MLN of FVB.Rag2<sup>-/-</sup> recipients 14 days after adoptive transfer. \* *P* < 0.01. Mean of 6 recipient mice per group + standard deviation shown.